Should patients with acute coronary disease be stratified for management according to their risk? Derivation, external validation and outcomes using the updated GRACE risk score
Keith A.A. Fox(University of Edinburgh), Fred Anderson(University of Massachusetts Chan Medical School)
Cited by 426
Related Papers
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
|New England Journal of Medicine|2011|1.9k
18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: a prospective clinical trial
|The Lancet|2013|942
Vorapaxar in the Secondary Prevention of Atherothrombotic Events
|New England Journal of Medicine|2012|941
International Day for the Evaluation of Abdominal Obesity (IDEA)
|Circulation|2007|707